Sodium-glucose transport proteins

Jun 18, 2020

Nephrologists Are Hesitant to Fully Embrace Janssen's INVOKANA Despite Being the First and Only SGLT2 Inhibitor with an FDA Indication to Treat Diabetic Kidney Disease

Jun 10, 2019

Sihuan's Abstracts regarding Clinical Trial Progress of SGLT-2 Inhibitor Selected for Poster Presentation at the American Diabetes Association's Scientific Sessions

May 24, 2018

New Review of the Real-world Data on the Cardiovascular Benefits Associated with the Use of Sodium-glucose Cotransporter 2 Inhibitors - touchENDOCRINOLOGY

Feb 26, 2018

New Data Show Lilly's Trulicity® (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes

Sep 08, 2017

Lexicon Pharmaceuticals Reports Positive Pooled Continuous Glucose Monitoring Data From Pivotal Phase 3 inTandem1 And inTandem2 Studies Of Sotagliflozin

Sep 05, 2017

Lexicon Pharmaceuticals to Present New Clinical Data at the European Association for the Study of Diabetes 53rd Annual Meeting

Jun 12, 2017

INVOKANA® (canagliflozin) Significantly Reduces the Combined Risk of Cardiovascular Death, Myocardial Infarction and Stroke in the CANVAS Program

Jun 05, 2017

Lexicon Pharmaceuticals To Present New Clinical Data At 77th American Diabetes Association Scientific Sessions